Lung cancer is the second most common type of cancer and the leading cause of cancer-related mortality (1). The discovery of oncogenic driver mutations and the development of immune checkpoint inhibitors has resulted in improved clinical outcomes for these patients. As systemic therapies continue to improve in the era of precision medicine, patients live longer and are thus at increased risk for brain metastases (2). Lung cancer, specifically non-small cell lung cancer (NSCLC), is the most common primary cancer associated with development of brain metastases with approximately 30–40% of affected patients developing brain metastases (1). Treatment of intracranial disease in this setting is multimodal and can include systemic therapy, surgery, stereotactic radiosurgery (SRS), whole brain radiotherapy (WBRT), and/or supportive care.

Molecular profiling of a lung cancer primary is standard practice and guides choice of first-line systemic therapy. The landscape of molecular alterations in a particular patient’s tumor has strong implications for survival. The Lung-molGPA is a tool for estimating survival in patients with lung cancer and brain metastases and accounts for this association of gene alteration and survival. Presence of EGFR and ALK gene alterations of the original primary lung tumor are considered positive prognostic factors for patients with NSCLC and brain metastases (2). Despite the connection between overall survival and the presence of a targetable mutation, analysis of molecular mutations is not a standard part of the decision-making paradigm for appropriate use of radiotherapy.

Press et al. recently conducted a study to examine the frequency and subtype of molecular alterations in patients with brain metastases from NSCLC and to identify markers associated with intracranial outcomes (3). In this retrospective study, 132 patients with metastatic NSCLC adenocarcinoma brain metastases and successful next-generation sequencing who were treated with intracranial radiotherapy were analyzed. The study demonstrated differences in outcomes for these patients based on molecular subtype of their primary tumor. Of particular clinical interest is their finding that patients with KRAS mutations and greater than six brain metastases have an increased risk of requiring salvage WBRT after having received upfront SRS for their intracranial disease. Such a finding has implications for the potential of molecular subtyping to guide radiotherapy decision making.

KRAS mutation is found in 25–30% of lung adenocarcinomas and is the most common oncogenic genetic event in NSCLC. Despite incredible progress in biomarker-driven targeted therapy for other NSCLC oncogenic mutations and rearrangements such as EGFR, ALK or ROS1, KRAS remains an elusive target for which there is currently no targeted therapy available. While many KRAS targeted agents have been evaluated in clinical trials, none have shown survival benefit (4). Interestingly, KRAS positive NSCLC has been implicated as an independent predictor for the development of brain metastases in some
studies (5).

For many years, the standard treatment for brain metastases was whole brain radiation therapy. As SRS became available in the 1980s as a second option for treatment of brain metastases, questions emerged regarding optimal patient stratification and overall efficacy for each modality. Broadly speaking, many studies for these purposes divided patients into two subgroups based on number of brain metastases: limited and multiple, with limited defined as the presence of 1–3 metastases and multiple defined as four or more. RTOG 9508 was a randomized trial that sought to investigate whether addition of SRS to WBRT could increase efficacy of treatment in patients with a limited number of brain metastases. The study found that addition of SRS to WBRT yields no difference in overall survival (6). Many later studies of patients with limited brain metastases again showed no overall survival benefit with WBRT and SRS versus SRS alone and additionally showed that SRS alone results in less neurocognitive deterioration at 3 months (7,8). Because WBRT is associated with worse neurocognition and the same overall survival, SRS is often given upfront for intracranial disease with WBRT reserved as salvage therapy for treatment of subsequent disease progression. Many studies are currently ongoing investigating outcomes for patients with multiple brain metastases. Multiple series, however, show that volume of intracranial disease is likely more important than number of metastases in determining prognosis (9). And most recently, mounting evidence, including that from Press et al., has shown that molecular subtyping plays an important role in patient outcome as well (3,10). In turn, one must ask if number of metastases is the best way to stratify patients, even initially, as appropriate candidates for SRS versus WBRT.

Currently, extensive and systematic analyses of the relationship between radiation efficacy and cancer genomics is lacking. This has prevented the movement of radiotherapy, a mainstay of anticancer treatment, into the age of precision medicine. Studies that identify frequent, potentially targetable, or prognostic genomic alterations that are correlated with the likelihood of response to radiation therapy are greatly needed. Press et al. is commended for taking a necessary step in this direction and relationship of genetic aberrations in patients with NSCLC adenocarcinoma brain metastases and their response to treatment with radiotherapy. A greater understanding of the interaction between the cancer genome and radiation will allow for more individualized treatment of patients based on tumor characteristics in addition to anatomic origin and has the potential to enhance effectiveness of treatment and limit toxicity in the event that genetic complexity of tumor cells also regulates therapeutic response to radiation.

Acknowledgements

None.

Footnote

Conflicts of Interest: Dr. TJ Wang reports personal fees and non-financial support from AbbVie, non-financial support from Merck, personal fees from AstraZeneca, personal fees from Doximity, non-financial support from Novocure, personal fees and non-financial support from Elekta and personal fees from Wolters Kluwer, outside the submitted work. EJ Buss has no conflicts of interest to declare.

References


